Federal Reports

Why We Did This Report

The U.S. Environmental Protection Agency Office of Inspector General conducted this audit to determine whether the EPA has sufficient controls over its grants management processes to monitor post-award performance of grants awarded with Infrastructure Investment and Jobs Act funding in accordance with federal grant requirements and other related EPA policies.
 

Summary of Findings

The EPA did not have controls in place to ensure that its regional offices are monitoring post-award performance of grants through required post-award monitoring plans and regular monitoring reviews. In addition, the regional offices did not always complete their baseline monitoring reports. Finally, of the 40 grant files we reviewed, 39 were not maintained in accordance with regional policy.

Audit of the Railroad Retirement Board’s                                                                RUIA Experience Rating Process

The audit concluded that the Peace Corps’ financial statements were fairly presented, in all material respects, in accordance with Generally Accepted Accounting Principles (GAAP), and noted two significant deficiencies in the agency’s internal control over financial reporting, as well as one instance of reportable noncompliance related to provisions of applicable laws, regulations, contracts, and grant agreements.

VHA pharmacies cannot dispense drugs that are damaged or expired or will be expiring soon. To address this issue and to recover some costs, VA contracted with Pharma Logistics LLC to provide national reverse distribution services, where manufacturers accept returned drugs in exchange for credits toward future purchases. Pharma Logistics collected returned drugs, sorted them, returned them to the manufacturers, disposed of nonreturnable products, and coordinated the application of credits from manufacturers to VA accounts. The OIG’s objective was to determine whether Pharma Logistics complied, in all material respects, with its contract regarding drug return credits and billing. Of the about $114.4 million in manufacturer credits for drugs that VA facilities expected from reverse distribution services as of March 2024, VA received only about $110.3 million. Of the $4.1 million variance, over $3.6 million of the unapplied credits were related to Pharma Logistics improperly closing jobs and $526,520 was used for contract-prohibited processing fees. VA agreed with the OIG’s three recommendations for it to confer with VA’s Office of General Counsel regarding the potential recovery of credits.

The National Security Agency (NSA) Office of the Inspector General (OIG) publicly released an unclassified version of its Semiannual Report (SAR) to Congress summarizing the OIG's oversight work during the second half of fiscal year 2025.

As required by the Inspector General Act of 1978, as amended (IG Act), the SAR was transmitted to Congress on 15 December 2025.

From May through June 2025, the GPO OIG office sent a joint team of investigators and inspectors to
GPO’s two Distribution Centers, as well as the Stennis Secure Production Facility (SPF). The purpose was to evaluate any actions taken by GPO to address the considerations outlined in the May 2022 GPO OIG Regional Site Visit Report.